House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Surgery

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG89 addresses prevention of hospital-acquired venous thromboembolism in people over sixteen. It requires assessment of both thrombosis and bleeding, then selection of prophylaxis according to the illness, procedure and clinical circumstances. The following selected pathways preserve their different timing and duration requirements; they are not a single regimen for every admission.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Assess competing risks and make the discharge plan

  • Assess VTE and bleeding risk promptly on hospital admission using an appropriate published tool. Balance the individual risks before pharmacological prophylaxis, and reassess medical, surgical and trauma patients at consultant review or whenever their condition changes. [1]
  • When pharmacological prophylaxis is indicated, the general medical and surgical/trauma recommendation is to start as soon as possible and within 14 hours of the admission decision, unless a population-specific recommendation gives different timing. [1]
  • Encourage early mobilisation and avoid dehydration unless clinically indicated. Explain prophylaxis benefits and harms, including bleeding, and ensure the person understands how to use mechanical or medication prophylaxis. [1]
  • At discharge, explain DVT and pulmonary-embolism symptoms, when to seek help, correct prophylaxis use and its intended duration. Ensure the person can administer or apply treatment, or has practical assistance, and notify the primary-care clinician when prophylaxis continues at home. [1]

Use compression safely

  • Do not use anti-embolism stockings with suspected or proven peripheral arterial disease, arterial bypass grafts, sensory impairment, damaging local skin conditions, material allergy, severe edema or inability to achieve a correct fit. Seek expert advice when arterial disease is suspected. [1]
  • Measure and fit stockings correctly, remeasure after swelling, and remove them daily for hygiene and skin inspection. Stop for skin marking, blistering, discoloration or pain; consider pneumatic compression if suitable. [1]

Select medical, critical-care and cancer pathways

  • For acutely ill medical patients whose VTE risk exceeds bleeding risk, offer pharmacological prophylaxis for at least 7 days. Use LMWH first line, or fondaparinux if LMWH is contraindicated. [1]
  • For immobile acute-stroke patients, consider pneumatic compression starting within 3 days and continue for 30 days or until mobility or discharge, whichever comes first. Do not use anti-embolism stockings for acute stroke. [1]
  • In critical care, provide LMWH when not contraindicated; consider mechanical prophylaxis if medication is contraindicated. Reassess thrombosis and bleeding at least daily and more often if the clinical state changes rapidly. [1]
  • For renal impairment, this guideline defines the group as eGFR below 30 ml/min/1.73 m². If pharmacological prophylaxis is used, choose LMWH or unfractionated heparin and reduce the dose when needed using senior or multidisciplinary advice or local protocols. [1]
  • Do not routinely offer prophylaxis solely for cancer-modifying treatment in mobile patients, except the specified myeloma and pancreatic-cancer groups or another increased-risk condition. These are this guideline’s selected ambulatory-cancer recommendations. [1]
  • Consider aspirin or LMWH for myeloma treated with thalidomide, pomalidomide or lenalidomide plus steroids, and consider LMWH for pancreatic cancer receiving chemotherapy. When prophylaxis is given for these indications, continue throughout chemotherapy. [1]
  • In palliative care, consider prophylaxis according to temporary thrombotic risks, bleeding, prognosis and patient preferences, and review daily. Do not offer VTE prophylaxis in the last days of life. [1]

Keep procedure-specific regimens distinct

  • For lower-limb immobilisation, consider LMWH or fondaparinux when VTE risk outweighs bleeding risk. Consider stopping prophylaxis if immobilisation extends beyond 42 days. [1]
  • For fragility fractures of the pelvis, hip or proximal femur, offer prophylaxis for a month when thrombosis risk outweighs bleeding. Options are LMWH beginning 6 to 12 hours after surgery or fondaparinux beginning at 6 hours if bleeding risk is low. [1]
  • For elective hip replacement when VTE risk exceeds bleeding risk, options include LMWH for 10 days followed by aspirin for 28 days, LMWH for 28 days plus stockings until discharge, or rivaroxaban under its appraisal. Aspirin doses listed are 75 mg or 150 mg. [1]
  • For elective knee replacement when VTE risk exceeds bleeding risk, options include aspirin 75 mg or 150 mg for 14 days, LMWH for 14 days plus stockings until discharge, or rivaroxaban under its appraisal. Consider pneumatic compression if pharmacological prophylaxis is contraindicated, until mobile. [1]

Respect bleeding control and anesthesia timing

  • For major trauma, offer pneumatic compression on admission until mobility is no longer significantly reduced, and reassess VTE and bleeding whenever the condition changes and at least daily. Consider pharmacological prophylaxis promptly after assessment when thrombosis risk exceeds bleeding risk, continuing for at least 7 days. [1]
  • For abdominal surgery, begin mechanical prophylaxis on admission and continue until mobility is no longer significantly reduced. Add LMWH or fondaparinux for at least 7 days when VTE risk exceeds bleeding risk, and consider extending medication prophylaxis to 28 days after major abdominal cancer surgery. [1]
  • When regional anesthesia is used, coordinate antiplatelet and anticoagulant timing to minimize epidural-hematoma risk and follow the relevant product guidance. Do not automatically apply the general admission-starting deadline to neuraxial procedures. [1]

Reassess pregnancy-related risk and avoid prophylaxis during labour

  • For admission during pregnancy or within 6 weeks after birth, miscarriage or termination, consider LMWH when VTE risk outweighs bleeding. Reassess within 6 hours after birth, miscarriage or termination and if the clinical condition changes. Do not offer prophylaxis in active labour, and stop pharmacological prophylaxis when labour begins. [1]
  • If LMWH is used after birth, miscarriage or termination, start 4 to 8 hours afterwards unless contraindicated and continue for at least 7 days. During pregnancy, start as soon as possible and within 14 hours of completed risk assessment and continue until risk resolves or discharge. [1]

Limitations and use

  • This is a selected prevention summary, not treatment for established DVT or pulmonary embolism. It omits dosing adjustments and many specialty surgical pathways, including cranial and spinal surgery.
  • Neuraxial procedures, intracranial bleeding and operation-specific timing require their full recommendations; the general admission deadline must not override them.
  • The ambulatory-cancer section reflects this guideline’s recommendations and is not a complete current oncology thrombosis-risk protocol.
  • Check product authorization and local dosing guidance, especially for people below eighteen, renal impairment and pregnancy; several source indications were identified as off label when published.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
21 March 2018
Publisher’s latest update
13 August 2019
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Assess competing risks and make the discharge plan
  • Use compression safely
  • Select medical, critical-care and cancer pathways
  • Keep procedure-specific regimens distinct
  • Respect bleeding control and anesthesia timing
  • Reassess pregnancy-related risk and avoid prophylaxis during labour
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House